Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.

Abstract

Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma\xa0(RRMM) patients. Materials & methods: Eligible patients had ≥1 line of therapy (LOT) each of proteasome inhibitors, immunomodulatory drugs\xa0and daratumumab in December 2015-September 2018 and received a new LOT. Results:\xa0A total of\xa0154 patients were included with a\xa0median follow-up of 6.2\xa0months. Median time from diagnosis to new LOT was 41.0\xa0months. Kaplan-Meier estimate of median time to therapy discontinuation was 4.2\xa0months. Mean per-patient, per-month MM-related costs were\xa0USD\xa035,657. Most frequently observed regimens were lenalidomide or pomalidomide\xa0+\xa0daratumumab (18.2%), lenalidomide or pomalidomide\xa0+\xa0proteasome inhibitors (15.6%) and lenalidomide or pomalidomide monotherapy (11.0%). Conclusion: Triple-class exposed RRMM patients receive heterogeneous treatments for a short duration with high healthcare resource utilization and costs.